Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

anti-ALK-1 monoclonal antibody GT90001

A human immunoglobulin G2 (IgG2) monoclonal antibody against activin receptor-like kinase-1 (ALK-1; ALK1), with potential anti-angiogenic and antineoplastic activities. Upon administration, anti-ALK-1 monoclonal antibody GT90001 targets and binds to ALK-1, and prevents ALK-1 activation by its ligands bone morphogenetic protein 9 (BMP) 9 and BMP10. This prevents ALK-1-mediated endothelial cell signaling and the activation of transforming growth factor-beta (TGF-beta)/TGF-beta receptor I (ALK-5) signaling. This inhibits tumor blood vessel growth, reduces blood flow and angiogenesis and leads to an inhibition of tumor cell proliferation and modulation of the tumor microenvironment (TME). ALK-1 is a type I cell surface receptor and plays a key role in angiogenesis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-activin receptor-like kinase-1 monoclonal antibody GT90001
Code name:GT9 0001
GT9-0001
GT90001
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search